[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1110391T1 - Αρυλβινυλαζακυκλοαλκανια και μεθοδοι παρασκευης και χρησεως τους - Google Patents

Αρυλβινυλαζακυκλοαλκανια και μεθοδοι παρασκευης και χρησεως τους

Info

Publication number
CY1110391T1
CY1110391T1 CY20081100831T CY081100831T CY1110391T1 CY 1110391 T1 CY1110391 T1 CY 1110391T1 CY 20081100831 T CY20081100831 T CY 20081100831T CY 081100831 T CY081100831 T CY 081100831T CY 1110391 T1 CY1110391 T1 CY 1110391T1
Authority
CY
Cyprus
Prior art keywords
disorders
compounds
disease
preparation
central nervous
Prior art date
Application number
CY20081100831T
Other languages
English (en)
Inventor
Jeffrey Daniel Schmitt
Gary Maurice Dull
Arielle Genevois-Borella
Marc Capet
Michel Cheve
Original Assignee
Targacept Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc. filed Critical Targacept Inc.
Publication of CY1110391T1 publication Critical patent/CY1110391T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Αποκαλύπτονται νέα βινυλαζακυκλοαλκάνια Τύπου (Ι). Οι ενώσεις είναι προσδέματα διαφόρων nAChR. Οι ενώσεις και τα φαρμακευτικά αποδεκτά άλατά τους μπορούν να χρησιμοποιηθούν για την παρασκευή φαρμακευτικών συνθέσεων και/ή φαρμάκων προοριζόμενων για την πρόληψη ή την αγωγή διαταραχών σχετιζόμενων με δυσλειτουργία των nAChR, ιδιαίτερα εντός του κεντρικού νευρικού συστήματος ή του γαστρεντερικού συστήματος. Παράδειγμα τύπων διαταραχών οι οποίες μπορούν να αντιμετωπισθούν περιλαμβάνουν νευροεκφυλιστικές διαταραχές, περιλαμβανομένων διαταραχών του κεντρικού νευρικού συστήματος όπως η νόσος του Alzheimer, νοητικές διαταραχές, κινητικές διαταραχές όπως η νόσος του Parkinson, τον εθισμό σε φάρμακα, διαταραχές της συμπεριφοράς και φλεγμονώδεις διαταραχές εντός του γαστρεντερικού συστήματος. Οι ενώσεις μπορούν επίσης να χρησιμεύουν ως αναλγητικά στην αγωγή του οξέως, χρόνιου ή υποτροπιάζοντος άλγους.
CY20081100831T 2003-03-05 2008-08-06 Αρυλβινυλαζακυκλοαλκανια και μεθοδοι παρασκευης και χρησεως τους CY1110391T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/379,868 US7098331B2 (en) 2003-03-05 2003-03-05 Arylvinylazacycloalkane compounds and methods of preparation and use thereof
EP04717398A EP1601670B1 (en) 2003-03-05 2004-03-04 Arylvinylazacycloalkane compounds and methods of preparation and use thereof

Publications (1)

Publication Number Publication Date
CY1110391T1 true CY1110391T1 (el) 2015-04-29

Family

ID=32926772

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20081100831T CY1110391T1 (el) 2003-03-05 2008-08-06 Αρυλβινυλαζακυκλοαλκανια και μεθοδοι παρασκευης και χρησεως τους
CY20111100351T CY1111615T1 (el) 2003-03-05 2011-04-05 Αρυλβινυλαζακυκλοαλκανια και μεθοδοι παρασκευης και χρησεως τους.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20111100351T CY1111615T1 (el) 2003-03-05 2011-04-05 Αρυλβινυλαζακυκλοαλκανια και μεθοδοι παρασκευης και χρησεως τους.

Country Status (32)

Country Link
US (8) US7098331B2 (el)
EP (3) EP2085395B1 (el)
JP (3) JP4663627B2 (el)
KR (4) KR100953150B1 (el)
CN (3) CN100526308C (el)
AR (3) AR043469A1 (el)
AT (3) ATE517893T1 (el)
AU (3) AU2004217903B2 (el)
BR (1) BRPI0409576A (el)
CA (1) CA2516514C (el)
CL (1) CL2004000452A1 (el)
CY (2) CY1110391T1 (el)
DE (2) DE602004031165D1 (el)
DK (2) DK1601670T3 (el)
EA (3) EA019240B1 (el)
ES (3) ES2309507T3 (el)
GT (1) GT200400033A (el)
HK (3) HK1084949A1 (el)
IL (3) IL170155A (el)
JO (1) JO2488B1 (el)
MX (1) MXPA05009386A (el)
NO (3) NO331920B1 (el)
NZ (1) NZ541795A (el)
PA (1) PA8597201A1 (el)
PE (1) PE20040930A1 (el)
PL (5) PL1601670T3 (el)
PT (2) PT1601670E (el)
SI (2) SI1601670T1 (el)
TW (3) TWI339662B (el)
UY (1) UY28218A1 (el)
WO (1) WO2004078752A1 (el)
ZA (1) ZA200506790B (el)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098331B2 (en) * 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
FR2896800B1 (fr) * 2006-01-30 2008-04-11 Servier Lab Nouveaux composes pyridinylaminoalkylene-et pyridinyloxyalkylene-cyclopropanamines polysubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
WO2008157365A2 (en) * 2007-06-15 2008-12-24 Targacept, Inc. Vinylazacycloalkanes for treating neuropathic pain
EP2296640A1 (en) * 2008-05-12 2011-03-23 Targacept Inc. Methods for preventing the development of retinopathy by the oral administration of nnr ligands
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
TW201024283A (en) * 2008-12-01 2010-07-01 Targacept Inc Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine
RU2533819C2 (ru) * 2008-12-01 2014-11-20 Таргасепт, Инк. Синтез и новые солевые формы (r)-5-((e)-2-(пирролидин-3-илвинил)пиримидина
WO2010080757A2 (en) 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
US20120157477A1 (en) * 2009-06-17 2012-06-21 Targacept, Inc. Reversal of l-dopa-induced dyskinesia by neuronal nicotinic receptor ligands
AU2010328419A1 (en) 2009-12-07 2012-06-21 Targacept, Inc. 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetylcholine receptor ligands
CA2792157A1 (en) * 2010-03-11 2011-09-15 Targacept, Inc. Arylvinylazacycloalkane compounds for constipation
US20110274628A1 (en) * 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
US20140081714A1 (en) * 2012-09-19 2014-03-20 Salesforce.Com, Inc. Systems and methods of rewarding users in an on-demand system
US20140278929A1 (en) * 2013-03-15 2014-09-18 Yahoo! Inc. System and method identifying opportunities for advertising entities based on user goal achievement
MX2018012230A (es) 2016-04-07 2019-03-28 Oyster Point Pharma Inc Métodos para tratar enfermedades oculares.
KR101848601B1 (ko) * 2016-07-27 2018-04-12 송기봉 일회용 위생 티슈
EP3820443A1 (en) 2018-07-10 2021-05-19 Oyster Point Pharma, Inc. Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions
WO2020014217A1 (en) 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Methods of treating ocular conditions
WO2021222230A1 (en) 2020-04-28 2021-11-04 Oyster Point Pharma, Inc. Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989000158A1 (en) 1987-07-02 1989-01-12 Pfizer Inc. Bridged-diazabicycloalkyl quinolone carboxylic acids and esters
US4922901A (en) * 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
US5187166A (en) * 1990-07-31 1993-02-16 Nisshin Flour Milling Co., Ltd. Azabicyclo derivatives and their use as antiemetics
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) * 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
IT1274018B (it) * 1994-02-23 1997-07-14 Riace Ets Derivati del 3,8-diazabiciclo(3.2.1.)ottano ad attivita' analgesica
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5604231A (en) * 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) * 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
US5663356A (en) * 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US6437138B1 (en) * 1996-06-06 2002-08-20 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US5629325A (en) 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
EP1027336B1 (en) 1997-10-27 2004-10-06 Neurosearch A/S Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors
WO2000075110A1 (en) 1999-06-07 2000-12-14 Targacept, Inc. Pharmaceutical compositions and methods for use
EP1212319A2 (en) 1999-09-14 2002-06-12 Abbott Laboratories 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission
CA2389645A1 (en) 1999-11-01 2001-05-10 Targacept, Inc. Aryl olefinic azacyclic, and aryl acetylenic azacyclic compounds, pharmaceutical compositions containing them and their use as inhibitors of nicotinic cholinergic receptors
US6624167B1 (en) * 2000-08-04 2003-09-23 Targacept, Inc. Pharmaceutical compositions and methods for use
US6881738B2 (en) 2001-07-19 2005-04-19 Medical College Of Georgia Research Institute Analogs of choline for neuroprotection and cognitive enhancement in neurodegenerative disorders
US7098331B2 (en) * 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof

Also Published As

Publication number Publication date
US8633222B2 (en) 2014-01-21
CN101255155A (zh) 2008-09-03
AR070570A2 (es) 2010-04-21
US7098331B2 (en) 2006-08-29
US20040176348A1 (en) 2004-09-09
NO332293B1 (no) 2012-08-20
KR20090021227A (ko) 2009-02-27
EA200501425A1 (ru) 2006-02-24
PL215059B1 (pl) 2013-10-31
NO20092231L (no) 2005-10-03
TW200927745A (en) 2009-07-01
ES2389106T3 (es) 2012-10-23
CN100526308C (zh) 2009-08-12
US7714001B2 (en) 2010-05-11
EP1601670B1 (en) 2008-05-07
CN101550132A (zh) 2009-10-07
PL378415A1 (pl) 2006-04-03
US20100267776A1 (en) 2010-10-21
HK1116800A1 (en) 2009-01-02
IL197890A (en) 2013-11-28
EP1947100A1 (en) 2008-07-23
KR101185541B1 (ko) 2012-09-24
EA014714B1 (ru) 2011-02-28
KR20060006006A (ko) 2006-01-18
JP5537084B2 (ja) 2014-07-02
CA2516514A1 (en) 2004-09-16
ZA200506790B (en) 2006-05-31
PT2085395E (pt) 2011-04-20
TW200505909A (en) 2005-02-16
US20150164894A1 (en) 2015-06-18
ATE394394T1 (de) 2008-05-15
JP2009292825A (ja) 2009-12-17
CN101550132B (zh) 2012-03-28
NO20091888L (no) 2005-10-03
AU2008258188B2 (en) 2011-02-24
KR101018083B1 (ko) 2011-03-02
PL394604A1 (pl) 2011-07-18
CL2004000452A1 (es) 2005-05-20
AU2008258188A1 (en) 2009-01-15
TWI377204B (en) 2012-11-21
HK1084949A1 (en) 2006-08-11
ES2385941T3 (es) 2012-08-03
JO2488B1 (en) 2009-10-05
EA200801764A1 (ru) 2008-12-30
KR20120014236A (ko) 2012-02-16
EA010870B1 (ru) 2008-12-30
ATE496046T1 (de) 2011-02-15
US8067443B2 (en) 2011-11-29
NO331920B1 (no) 2012-04-30
PL2085395T3 (pl) 2011-05-31
AU2004217903B2 (en) 2010-03-04
CA2516514C (en) 2012-02-07
NO20054120L (no) 2005-10-03
DE602004013553D1 (de) 2008-06-19
IL197889A (en) 2013-03-24
EA019240B1 (ru) 2014-02-28
EA200900706A1 (ru) 2009-10-30
SI1601670T1 (sl) 2008-10-31
TW200927746A (en) 2009-07-01
US20110152293A1 (en) 2011-06-23
PL216979B1 (pl) 2014-06-30
US20100010042A1 (en) 2010-01-14
AR070569A2 (es) 2010-04-21
SI2085395T1 (sl) 2011-05-31
PL394600A1 (pl) 2011-07-18
CY1111615T1 (el) 2015-10-07
JP2010001296A (ja) 2010-01-07
US8063068B2 (en) 2011-11-22
TWI339662B (en) 2011-04-01
EP1947100B1 (en) 2011-07-27
AU2008258187B2 (en) 2010-08-05
GT200400033A (es) 2005-05-29
CN1756754A (zh) 2006-04-05
AU2008258187A1 (en) 2009-01-15
PL1601670T3 (pl) 2008-10-31
UY28218A1 (es) 2005-06-30
DK1601670T3 (da) 2008-08-25
IL170155A (en) 2013-08-29
JP4663627B2 (ja) 2011-04-06
KR20090021228A (ko) 2009-02-27
ATE517893T1 (de) 2011-08-15
NZ541795A (en) 2008-03-28
DK2085395T3 (da) 2011-04-18
KR100953150B1 (ko) 2010-04-19
PA8597201A1 (es) 2004-09-28
JP5537085B2 (ja) 2014-07-02
DE602004031165D1 (de) 2011-03-03
EP2085395A1 (en) 2009-08-05
MXPA05009386A (es) 2005-11-04
EP1601670A1 (en) 2005-12-07
AU2004217903A1 (en) 2004-09-16
US20060094732A1 (en) 2006-05-04
US20080293778A1 (en) 2008-11-27
AR043469A1 (es) 2005-07-27
ES2309507T3 (es) 2008-12-16
PE20040930A1 (es) 2005-02-18
BRPI0409576A (pt) 2006-04-18
US20140107164A1 (en) 2014-04-17
EP2085395B1 (en) 2011-01-19
NO20054120D0 (no) 2005-09-05
HK1130254A1 (en) 2009-12-24
PT1601670E (pt) 2008-07-11
JP2006519868A (ja) 2006-08-31
WO2004078752A1 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
CY1110391T1 (el) Αρυλβινυλαζακυκλοαλκανια και μεθοδοι παρασκευης και χρησεως τους
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
CY1108514T1 (el) Παραγωγα 1-φαινυλαλκανεκαρβοξυλικου οξεος για τη θεραπεια νευρογενων ασθενειων
CY1118849T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
DE69912808D1 (de) Verwendung von Hymenialdisin und dessen Derivaten zur Herstellung therapeutischer Mittel
ATE407928T1 (de) Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung
DE60238999D1 (de) Aminoindazolderivate mit kinaseinhibierender wirkung, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
ATE285773T1 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
TW200501958A (en) A therapeutic agent for treating a behavioral disorder
WO2005094497A3 (en) Systemic delivery of therapeutics to central nervous system
HUP0303921A2 (hu) Dezoxipeganin alkalmazása pszihotrop anyagok okozta kóros központi idegrendszeri tünetek kezelésére
RU99107828A (ru) Способ лечения патологического влечения к наркотикам у больных опийной наркоманией
JP2006514659A5 (el)
RU2002109170A (ru) Способ лечения больных хроническими цереброваскулярными заболеваниями